Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease

NCT ID: NCT00440245

Last Updated: 2020-03-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-02-28
• Study Completion Date: 2010-07-31

Brief Summary

This study will investigate potential differences in how two puffs of salbutamol protects airway smooth muscle from contracting in people with asthma and chronic obstructive pulmonary disease (COPD).

Detailed Description

In asthma, the administration (inhalation) of a selective β2 receptor agonist (e.g. salbutamol), prior to methacholine challenge has been shown to shift the dose response curve to the right and "bronchoprotect" the airway against airway smooth muscle contraction. The extent of β2 receptor agonist bronchoprotection in COPD is unknown.

Airway hyperresponsiveness (AHR) to direct acting agents such as histamine and methacholine is a feature of both asthma and COPD. In asthma, the abnormality leading to AHR is believed to be due to changes in airway smooth muscle (e.g. hypertrophy, hyperplasia, contractile apparatus) whereas in COPD the AHR is likely due to structural or geometric changes.

The investigators hypothesize that the bronchoprotection afforded by salbutamol against methacholine challenge will be greater in asthma than in COPD due to differences in underlying airway abnormalities.

Conditions

Asthma; COPD

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

salbutamol

There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).

Group Type: OTHER

salbutamol

Intervention Type: DRUG

200 micrograms salbutamol from MDI

Interventions

salbutamol

200 micrograms salbutamol from MDI

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• asthma or COPD

Exclusion Criteria

• asthma and COPD

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Saskatchewan

OTHER

Sponsor Role: lead

Responsible Party

Don Cockcroft

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Donald Cockcroft, MD

Role: PRINCIPAL_INVESTIGATOR

University of Saskatchewan

Locations

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Countries

Canada

Other Identifiers

Bio-REB 06-231

Identifier Type: -

Identifier Source: org_study_id